ClinicalTrials.gg
CompletedNCT03734016ALPINEUpdated Mar 30, 2025Results posted

A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

A Phase 3 interventional study of Zanubrutinib and Ibrutinib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by BeiGene. Completed at 115 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by BeiGene · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
652
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 11 open to participants now, 17 under way, 3 of them phase 3. zanubrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
Largest of 22
652 · median 71
Started
2018
the only one that year
Phase 3
4 of 22
1 open now
Registered
3rd of 22
by date
Lead sponsor
5 of 22
BeiGene

Among the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment, is the only one that started in 2018, is one of 4 in phase 3, and was the 3rd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

11 of the 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About zanubrutinib

zanubrutinib: first FDA approval 2019 (BRUKINSA), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing zanubrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This study is designed to compare the overall response rate of zanubrutinib versus ibrutinib in participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Read the detailed description

This is a global, Phase 3, randomized study of zanubrutinib versus ibrutinib in 652 participants with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

The primary efficacy endpoint is overall response rate determined by investigator assessment. Participants were randomized in a 1:1 manner to either zanubrutinib or ibrutinib. Treatment with zanubrutinib and ibrutinib was open label.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • CLL
  • SLL
  • relapsed
  • refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  1. Confirmed diagnosis of CLL or SLL that meets the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria
  2. CLL/SLL requiring treatment per 2008 IWCLL criteria
  3. to at least 1 prior systemic therapy for CLL/SLL
  4. by computerized tomography (CT)/magnetic resonance imaging (MRI)
  5. (ECOG) performance status of 0, 1, or 2
  6. ≥ 6 months
  7. Adequate bone marrow function
  8. Adequate renal and hepatic function

Key Exclusion Criteria

  1. Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation
  2. cardiovascular disease.
  3. Prior within the past 3 years, except for curatively treated basal or squamous cell skin cancer, non-muscle-invasive bladder cancer, carcinoma in situ of the cervix or breast
  4. History of severe bleeding disorder or history of spontaneous bleeding requiring blood transfusion or other medical intervention
  5. History of stroke or intracranial hemorrhage within 180 days before first dose of study drug
  6. Severe or debilitating pulmonary disease
  7. Active fungal, bacterial, and/or viral infection requiring systemic therapy
  8. Known central nervous system involvement by leukemia or lymphoma
  9. Known infection with or active viral or C infection
  10. Moderate or severe hepatic impairment, ie, class B or C
  11. Major surgery within 4 weeks of the first dose of study drug
  12. Prior treatment with a (Burton's Kinase) BTK inhibitor
  13. Toxicity from prior anticancer therapy that has not recovered to ≤ Grade 1
  14. Pregnant or lactating women
  15. Vaccination with a within 35 days prior to the first dose of study drug
  16. to zanubrutinib, ibrutinib, or any of the other ingredients in either drug
  17. Concurrent participation in another therapeutic clinical trial

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
652 participants (actual)

Study arms

  • Experimental
    Zanubrutinib

    Participants received 160 mg zanubrutinib orally twice daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.

    Drug: Zanubrutinib

  • Active comparator
    Ibrutinib

    Participants received Ibrutinib 420 mg orally once daily until disease progression, intolerable toxicity, initiation of alternative anticancer therapy, investigator/Sponsor decision, need for prohibited medication, study withdrawal, or pregnancy.

    Drug: Ibrutinib

Interventions

  • 160 mg orally twice daily

    Also known as: BGB-3111, Brukinsa

  • Ibrutinib 420 mg orally once daily

    Also known as: Imbruvica

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) Assessed by the Investigator

    ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) per investigator assessment. Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  2. ORR Assessed by the Independent Review Committee (IRC)

    ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) assessed by a blinded independent review committee. Overall response was assessed by the IRC for the purpose of regulatory filing with the Food and Drug Administration (FDA). Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

Secondary outcomes

  1. Progression-free Survival (PFS) Assessed by the Investigator

    PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  2. Progression-free Survival Assessed by the Independent Review Committee

    PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  3. Percentage of Participants With Atrial Fibrillation or Atrial Flutter

    Participants were considered as having an atrial fibrillation/flutter event if they had a treatment-emergent AE of either "atrial fibrillation" or "atrial flutter".

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  4. Duration of Response Assessed by the Independent Review Committee

    DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by independent central review. Median DOR was estimated using the Kaplan-Meier method.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  5. Duration of Response (DOR) Assessed by the Investigator

    DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by investigator assessment. Median DOR was estimated using the Kaplan-Meier method.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  6. Time to Treatment Failure

    Time to treatment failure is defined as the time from randomization to discontinuation of study drug due to any reason. Median time to treatment failure was estimated by the Kaplan-Meier method.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  7. Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee

    The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or a complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis assessed by the blinded IRC. Disease response was assessed per iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and per Lugano classification for participants with SLL.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  8. Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Investigator

    The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis as assessed by the investigator. Disease response was assessed according to the iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and in accordance with Lugano classification for participants with SLL. Partial response with lymphocytosis: blood lymphocytes decreased \< 50% or increased from baseline, and otherwise meeting criteria for PR.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  9. Overall Survival (OS)

    Overall survival is defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

    Time frame: From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).

  10. Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

    Time frame: Baseline and Weeks 24 and 48

  11. Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea

    The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores in symptom scales indicate better quality of life.

    Time frame: Baseline and Weeks 24 and 48

  12. Change From Baseline in European Quality of Life 5-dimensions 5-levels Health Questionnaire (EQ-5D-5L) Visual Analog Scale (VAS)

    The EQ-5D-5L VAS measures a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

    Time frame: Baseline and Weeks 24 and 48

  13. Number of Participants With Treatment-emergent Adverse Events (TEAE)

    An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Resulted in a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgment

    Time frame: From first dose of study drug up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm.

07

Results

Posted Jul 27, 2023

Participant flow

This study was conducted at 113 study centers in 15 countries (Australia, Belgium, China, the Czech Republic, France, Germany, Italy, the Netherlands, New Zealand, Poland, Spain, Sweden, Turkey, the United Kingdom, and the United States).

Participant flow — Overall Study
MilestoneZanubrutinibIbrutinib
Started327325
Received study drug324324
Completed00
Not completed327325
Withdrew: Sponsor ended study225200
Withdrew: Death6983
Withdrew: Withdrawal by subject2127
Withdrew: Physician decision112
Withdrew: Lost to follow-up62
Withdrew: Miscellaneous51

Outcome measures

PrimaryOverall Response Rate (ORR) Assessed by the Investigator

ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) per investigator assessment. Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) Assessed by the Investigator
percentage of participantsZanubrutinibIbrutinib
Overall Response Rate (ORR) Assessed by the Investigator83.5 (79.0 to 87.3)74.2 (69.0 to 78.8)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Stratified Wald test · p = <0.0001 · Response ratio: 1.12 · 95% CI 1.04 to 1.22Response ratio is the estimated ratio of the overall response rate of the zanubrutinib arm divided by that of the ibrutinib arm.
  • Zanubrutinib vs Ibrutinib · Cochran-Mantel-Haenszel · p = 0.0035 (Superiority testing was performed using a 2-sided stratified Cochran-Mantel-Haenszel test.)Stratified by the randomization stratification factors (age, geographic region, refractory status, and 17p deletion and TP53 mutation status)
PrimaryORR Assessed by the Independent Review Committee (IRC)

ORR is defined as the percentage of participants with a complete response (CR) / complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) assessed by a blinded independent review committee. Overall response was assessed by the IRC for the purpose of regulatory filing with the Food and Drug Administration (FDA). Disease response was assessed in accordance with the 2008 criteria of the International Workshop on CLL (IWCLL), with modification for treatment-related lymphocytosis in participants with CLL and in accordance with the Lugano classification in participants with SLL.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Number · percentage of participants
ORR Assessed by the Independent Review Committee (IRC)
percentage of participantsZanubrutinibIbrutinib
ORR Assessed by the Independent Review Committee (IRC)86.2 (82.0 to 89.8)75.7 (70.7 to 80.3)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Stratified Wald test · p = <0.0001 · Response ratio: 1.14 · 95% CI 1.05 to 1.22Response ratio is the estimated ratio of the overall response rate of the zanubrutinib arm divided by that of the ibrutinib arm.
  • Zanubrutinib vs Ibrutinib · Cochran-Mantel-Haenszel · p = 0.0007Stratified by the randomization stratification factors (age, geographic region, refractory status, and 17p deletion and TP53 mutation status)
SecondaryProgression-free Survival (PFS) Assessed by the Investigator

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Median · months
Progression-free Survival (PFS) Assessed by the Investigator
monthsZanubrutinibIbrutinib
Progression-free Survival (PFS) Assessed by the InvestigatorNA (34.3 to NA)34.2 (33.3 to NA)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Stratified Wald test · p = <0.0001 · Hazard ratio (hr): 0.65 · 95% CI 0.49 to 0.86Hazard ratio is the ratio of the hazard of the zanubrutinib arm divided by that of the ibrutinib arm.
  • Zanubrutinib vs Ibrutinib · Stratified Log-rank test · p = 0.0024Stratified by the randomization stratification factors (age, geographic region, refractory status, and 17p deletion and TP53 mutation status)
SecondaryProgression-free Survival Assessed by the Independent Review Committee

PFS is defined as the time from randomization to the date of first documentation of disease progression or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Median · months
Progression-free Survival Assessed by the Independent Review Committee
monthsZanubrutinibIbrutinib
Progression-free Survival Assessed by the Independent Review CommitteeNA (34.3 to NA)35.0 (33.2 to 44.3)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Stratified Wald test · p = <0.0001 (Stratified by the randomization stratification factors (age, geographic region, refractory status, and 17p deletion and TP53 mutation status)) · Hazard ratio (hr): 0.65 · 95% CI 0.49 to 0.86Hazard ratio is the ratio of the hazard of the zanubrutinib arm divided by that of the ibrutinib arm.
  • Zanubrutinib vs Ibrutinib · Stratified Log-rank test · p = 0.0024Stratified by the randomization stratification factors (age, geographic region, refractory status, and 17p deletion and TP53 mutation status)
SecondaryPercentage of Participants With Atrial Fibrillation or Atrial Flutter

Participants were considered as having an atrial fibrillation/flutter event if they had a treatment-emergent AE of either "atrial fibrillation" or "atrial flutter".

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Number · percentage of participants
Percentage of Participants With Atrial Fibrillation or Atrial Flutter
percentage of participantsZanubrutinibIbrutinib
Percentage of Participants With Atrial Fibrillation or Atrial Flutter5.2 (3.1 to 8.3)13.3 (9.8 to 17.5)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Chi-squared · p = 0.0004 · Rate difference: -8.0 · 95% CI -12.4 to -3.6Rate difference is the zanubrutinib rate minus the ibrutinib rate.
SecondaryDuration of Response Assessed by the Independent Review Committee

DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by independent central review. Median DOR was estimated using the Kaplan-Meier method.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Median · months
Duration of Response Assessed by the Independent Review Committee
monthsZanubrutinibIbrutinib
Duration of Response Assessed by the Independent Review CommitteeNA (31.3 to NA)33.9 (32.2 to 41.4)
SecondaryDuration of Response (DOR) Assessed by the Investigator

DOR is defined as the time from the date that response criteria were first met to the date that disease progression was objectively documented or death, whichever occurred first, determined by investigator assessment. Median DOR was estimated using the Kaplan-Meier method.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Median · months
Duration of Response (DOR) Assessed by the Investigator
monthsZanubrutinibIbrutinib
Duration of Response (DOR) Assessed by the InvestigatorNA (31.3 to NA)33.9 (33.9 to NA)
SecondaryTime to Treatment Failure

Time to treatment failure is defined as the time from randomization to discontinuation of study drug due to any reason. Median time to treatment failure was estimated by the Kaplan-Meier method.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Median · months
Time to Treatment Failure
monthsZanubrutinibIbrutinib
Time to Treatment FailureNA (NA to NA)NA (34.4 to NA)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Hazard ratio (hr): 0.54 · 95% CI 0.41 to 0.72Hazard ratio is the ratio of the hazard of the zanubrutinib arm divided by that of the ibrutinib arm.
SecondaryRate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee

The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or a complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis assessed by the blinded IRC. Disease response was assessed per iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and per Lugano classification for participants with SLL.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Number · percentage of participants
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee
percentage of participantsZanubrutinibIbrutinib
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Independent Review Committee91.7 (88.2 to 94.5)83.1 (78.5 to 87.0)
SecondaryRate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Investigator

The rate of partial response with lymphocytosis or better is defined as the percentage of participants who achieved a complete response or complete response with incomplete bone marrow recovery (CR/CRi), nodular partial response, partial response, or partial response with lymphocytosis as assessed by the investigator. Disease response was assessed according to the iwCLL 2008 criteria, with modification for treatment-related lymphocytosis for participants with CLL and in accordance with Lugano classification for participants with SLL. Partial response with lymphocytosis: blood lymphocytes decreased \< 50% or increased from baseline, and otherwise meeting criteria for PR.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Number · percentage of participants
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Investigator
percentage of participantsZanubrutinibIbrutinib
Rate of Partial Response With Lymphocytosis (PR-L) or Higher Assessed by the Investigator89.9 (86.1 to 93.0)82.5 (77.9 to 86.4)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization to the date of death due to any cause. Median OS was estimated using the Kaplan-Meier method.

Time frame:
From randomization to the final efficacy analysis cutoff date of 08 August 2022, median time on follow-up was 29.6 months (maximum of 45.2 months).
Reported as:
Median · months
Overall Survival (OS)
monthsZanubrutinibIbrutinib
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Hazard ratio (hr): 0.76 · 95% CI 0.51 to 1.11Hazard ratio is the ratio of the hazard of the zanubrutinib arm divided by that of the ibrutinib arm.
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Higher scores in GHS and functional scales indicate better quality of life.

Time frame:
Baseline and Weeks 24 and 48
Reported as:
Least squares mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL), Physical Functioning and Role Functioning Scores
score on a scaleZanubrutinibIbrutinib
GHS/QoL Scale at Week 248.18 (6.25 to 10.12)5.18 (3.20 to 7.17)
GHS/QoL Scale at Week 487.28 (5.41 to 9.15)5.93 (3.97 to 7.89)
Physical Functioning Scale at Week 246.55 (4.96 to 8.15)4.73 (3.08 to 6.38)
Physical Functioning Scale at Week 485.46 (3.87 to 7.04)4.31 (2.65 to 5.97)
Role Functioning Scale at Week 246.95 (4.85 to 9.06)6.32 (4.14 to 8.50)
Role Functioning Scale at Week 486.81 (4.61 to 9.02)5.01 (2.69 to 7.33)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.0338 · Least squares (ls) mean difference: 3.00 · 95% CI 0.23 to 5.77
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.3304 · Ls mean difference: 1.34 · 95% CI -1.37 to 4.06
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.1189 · Ls mean difference: 1.82 · 95% CI -0.47 to 4.12
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.3274 · Ls mean difference: 1.15 · 95% CI -1.15 to 3.44
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.6821 · Ls mean difference: 0.63 · 95% CI -2.40 to 3.66
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.2701 · Ls mean difference: 1.80 · 95% CI -1.40 to 5.00
SecondaryChange From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life (QOL) questions answered on a 7-point scale where 1 = Very poor and 7 = Excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. Lower scores in symptom scales indicate better quality of life.

Time frame:
Baseline and Weeks 24 and 48
Reported as:
Least squares mean · score on a scale
Change From Baseline in EORTC QLQ-C30 Symptom Scales of Fatigue, Nausea and Vomiting, Pain, and Diarrhoea
score on a scaleZanubrutinibIbrutinib
Fatigue Symptom Scale at Week 24-12.54 (-14.47 to -10.60)-10.63 (-12.63 to -8.62)
Fatigue Symptom Scale at Week 48-11.13 (-13.19 to -9.08)-10.78 (-12.93 to -8.63)
Nausea and Vomiting Symptom Scale at Week 24-1.21 (-2.03 to -0.38)-0.92 (-1.77 to -0.07)
Nausea and Vomiting Symptom Scale at Week 48-0.92 (-1.94 to 0.10)-0.40 (-1.47 to 0.66)
Pain Symptom Scale at Week 24-5.06 (-7.21 to -2.91)-3.63 (-5.85 to -1.42)
Pain Symptom Scale at Week 48-5.18 (-7.38 to -2.97)-2.75 (-5.06 to -0.44)
Diarrhoea Symptom Scale at Week 24-2.11 (-3.80 to -0.42)-0.52 (-2.27 to 1.22)
Diarrhoea Symptom Scale at Week 48-3.23 (-4.79 to -1.66)-1.38 (-3.03 to 0.27)
Statistical analysis
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.1778 · Ls mean difference: -1.91 · 95% CI -4.70 to 0.87
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.8174 · Ls mean difference: -0.35 · 95% CI -3.32 to 2.62
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.6294 · Ls mean difference: -0.29 · 95% CI -1.48 to 0.89
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.4933 · Ls mean difference: -0.51 · 95% CI -1.99 to 0.96
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.3643 · Ls mean difference: -1.43 · 95% CI -4.51 to 1.66
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.1363 · Ls mean difference: -2.43 · 95% CI -5.62 to 0.77
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.2001 · Ls mean difference: -1.59 · 95% CI -4.01 to 0.84
  • Zanubrutinib vs Ibrutinib · Mixed model for repeated measures (MMRM) · p = 0.1121 · Ls mean difference: -1.85 · 95% CI -4.12 to 0.43
SecondaryChange From Baseline in European Quality of Life 5-dimensions 5-levels Health Questionnaire (EQ-5D-5L) Visual Analog Scale (VAS)

The EQ-5D-5L VAS measures a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.

Time frame:
Baseline and Weeks 24 and 48
Reported as:
Mean · score on a scale
Change From Baseline in European Quality of Life 5-dimensions 5-levels Health Questionnaire (EQ-5D-5L) Visual Analog Scale (VAS)
score on a scaleZanubrutinibIbrutinib
Week 247.92 ± 18.2453.44 ± 16.972
Week 487.75 ± 18.8063.92 ± 16.778
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAE)

An adverse event is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. A serious adverse event (SAE) is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Resulted in a congenital anomaly/birth defect * Was considered a significant medical AE by the investigator based on medical judgment

Time frame:
From first dose of study drug up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE)
ParticipantsZanubrutinibIbrutinib
Any TEAE322323
Serious adverse events172196

Adverse events

Collected over All-cause mortality was collected through the end of study, maximum time on study was 60.5 months. Adverse events were collected up to 30 days after last dose, up to the end of study data cutoff (28 February 2024); median (range) time on treatment was 41.2 (0.4-59.1) months in the zanubrutinib arm and 37.8 (0.1-60.4) months in the ibrutinib arm.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib69/327 (21.1%)172/324 (53.1%)310/324 (95.7%)
Ibrutinib83/325 (25.5%)196/324 (60.5%)314/324 (96.9%)
Most frequent serious events
Showing 10 of 299
Most frequent serious events
EventZanubrutinibIbrutinib
COVID-19 pneumoniaInfections and infestations33/32422/324
PneumoniaInfections and infestations24/32433/324
COVID-19Infections and infestations28/32420/324
Atrial fibrillationCardiac disorders2/32411/324
Urinary tract infectionInfections and infestations7/32410/324
AnaemiaBlood and lymphatic system disorders5/3244/324
PyrexiaGeneral disorders2/3245/324
DeathGeneral disorders4/3243/324
SepsisInfections and infestations4/3243/324
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/3241/324
Most frequent other events
Showing 10 of 101
Most frequent other events
EventZanubrutinibIbrutinib
COVID-19Infections and infestations121/32484/324
Upper respiratory tract infectionInfections and infestations95/32464/324
DiarrhoeaGastrointestinal disorders61/32483/324
HypertensionVascular disorders82/32474/324
NeutropeniaBlood and lymphatic system disorders81/32473/324
ArthralgiaMusculoskeletal and connective tissue disorders54/32463/324
AnaemiaBlood and lymphatic system disorders53/32456/324
FatigueGeneral disorders36/32449/324
ContusionInjury, poisoning and procedural complications49/32438/324
CoughRespiratory, thoracic and mediastinal disorders46/32443/324

Baseline characteristics

Intent-to-Treat (ITT) Analysis Set includes all randomized participants

Age, Categorical
Age, Categorical(Participants)ZanubrutinibIbrutinibTotal
<=18 years000
Between 18 and 65 years126125251
>=65 years201200401
Age, Continuous
Age, Continuous(years)ZanubrutinibIbrutinibTotal
Median67.0 (35 to 90)68.0 (35 to 89)67.0 (35 to 90)
Sex: Female, Male
Sex: Female, Male(Participants)ZanubrutinibIbrutinibTotal
Female11493207
Male213232445
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ZanubrutinibIbrutinibTotal
Hispanic or Latino71320
Not Hispanic or Latino309298607
Unknown or Not Reported111425
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ZanubrutinibIbrutinibTotal
Asian474491
Black or African American426
Native Hawaiian or Pacific Islander303
White261265526
Other224
Multiple101
Unknown/Not Reported91221
Geographic Region
Geographic Region(Participants)ZanubrutinibIbrutinibTotal
Asia494594
Australia/New Zealand283058
Europe198191389
North America5259111
Chromosome 17p Deletion (del[17p]) and TP53 Mutation Status
Chromosome 17p Deletion (del[17p]) and TP53 Mutation Status(Participants)ZanubrutinibIbrutinibTotal
Del(17p) and/or TP53 mutation7575150
Neither Del(17p) nor TP53 mutation251250501
Missing101
08

Study locations

115 sites
  • Carti Cancer Center
    Little Rock, Arkansas 72205, United States
  • David Geffen School of Medicine At UCLA
    Los Angeles, California 90095, United States
  • Rocky Mountain Cancer Centers Boulder
    Boulder, Colorado 80303, United States
  • Scri Florida Cancer Specialists South
    Fort Myers, Florida 33901, United States
  • Scri Florida Cancer Specialists North
    Saint Petersburg, Florida 33705, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Norton Cancer Institute Pavilion
    Louisville, Kentucky 40207, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Forrest General Hospital Cancer Center
    Hattiesburg, Mississippi 39401, United States
  • Scri Hca Midwest Health
    Kansas City, Missouri 64132, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Atlantic Health System
    Morristown, New Jersey 07960, United States
  • Morristown Medical Center
    Morristown, New Jersey 07960, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Clinical Research Alliance, Inc
    Westbury, New York 11590, United States
  • Duke University Hospital
    Durham, North Carolina 27705, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Willamette Valley Cancer Center
    Springfield, Oregon 97477, United States
  • Scri Tennessee Oncology Chattanooga
    Chattanooga, Tennessee 37404, United States
  • Sarah Cannon Cancer Center
    Nashville, Tennessee 37203, United States
  • Texas Oncology Fort Worth Cancer Center
    Fort Worth, Texas 76104-2150, United States
  • The University of Texas Md Anderson Cancer Center
    Houston, Texas 77030-4009, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Texas Oncology San Antonio Medical Center Usor
    San Antonio, Texas 78240, United States
  • Texas Oncology Tyler Longview
    Tyler, Texas 75702, United States
  • Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia)
    Roanoke, Virginia 24014, United States
  • Va Puget Sound Health Care System
    Seattle, Washington 98108, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
  • Medical Oncology Associates
    Spokane, Washington 99208, United States
  • Calvary Mater Newcastle
    Waratah, New South Wales 2298, Australia
  • Princess Alexandra Hospital
    Brisbane, Queensland 4102, Australia
  • Icon Cancer Foundation
    South Brisbane, Queensland 4101, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Peninsula Private Hospital
    Frankston, Victoria 3199, Australia
  • Royal Perth Hospital
    Perth, Western Australia 6000, Australia
  • Gasthuiszusters Antwerpen Sint Augustinus
    Wilrijk, 2610, Belgium
  • Peking University Third Hospital
    Beijing, Beijing 100000, China
  • Beijing Friendship Hospital, Capital Medical University
    Beijing, Beijing 100050, China
  • Peking Union Medical College Hospital
    Beijing, Beijing 100730, China
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
  • Quanzhou First Affliated Hospital of Fujian Medical University
    Quanzhou, Fujian 362000, China
  • Guangdong Provincial Peoples Hospital
    Guangzhou, Guangdong 510080, China
  • Nanfang Hospital of Southern Medical University
    Guangzhou, Guangdong 510515, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Shengjing Hospital of China Medical University
    Shenyang, Liaoning 110004, China
  • Affiliated Zhongshan Hospital of Fudan University
    Shanghai, Shanghai 200032, China
  • Tongji Hospital of Tongji University
    Shanghai, Shanghai 200092, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin 300020, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310003, China
  • The First Provincial Wenzhou Hospital of Zhejiang
    Wenzhou, Zhejiang 325000, China
  • Fakultni Nemocnice Brno
    Brno, 62500, Czechia
  • Fakultni Nemocnice Hradec Kralove
    Hradec Kralove, 50005, Czechia
  • Fakultni Nemocnice Olomouc
    Olomouc, 77900, Czechia
  • Fakultni Nemocnice Ostrava
    Ostrava, 708 00, Czechia
  • Hopital Prive Sevigne
    Cesson Sevigne, 35510, France
  • Centre Hospitalier Departemental de Vendee
    La Roche sur Yon, 85925, France
  • Centre Hospitalier Le Mans
    Le Mans, 72037, France
  • Chu Hopital Lyon Sud
    PierreBenite, 69495, France
  • Centre Hospitalier Universitaire de Poitier Hopital de La Miletrie Hopital Jean Bernard
    Poitiers, 86000, France
  • Chu Tours Hopital Bretonneau Service Pneumologie
    Tours, 37000, France
  • Evangelisches Krankenhaus Hamm
    Hamm, 59063, Germany
  • Uniklinik Koln (Aor)
    Koln, 50937, Germany
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda
    Milano, 20162, Italy
  • Fondazione Policlinico Universitario Agostino Gemelli
    Roma, 00168, Italy
  • Azienda Ospedaliera Citta Della Salute E Della Scienza Di Torino
    Torino, 10126, Italy
  • Gelre Ziekenhuizen
    Apeldoorn, 7334 DZ, Netherlands
  • Albert Schweitzer Ziekenhuis
    Nijmegen, 6525 GA, Netherlands
  • Middlemore Clinical Trials
    Auckland, 2025, New Zealand
  • Christchurch Hospital (Canterbury Health Laboratories)
    Christchurch, 8011, New Zealand
  • Waikato Hospital
    Hamilton, 3204, New Zealand
  • North Shore Hospital
    Takapuna, 0622, New Zealand
  • Tauranga Hospital
    Tauranga, 3112, New Zealand
  • Wellington Regional Hospital (Ccdhb)
    Wellington, 6021, New Zealand
  • Interhem Opieka Szpitalna
    Bialystok, 15748, Poland
  • Szpital Specjalist W Brzozowie,Podkarpacki Osrodek Onkologiczny
    Brzozow, 36-200, Poland
  • Samodzielny Publiczny Zaklad Opieki Zdrowotnej Zespol Szpitali Miejskich
    Chorzow, 41-500, Poland
  • Copernicus Podmiot Leczniczy Sp Z Oo Wojewodzkie Centrum Onkologii
    Gdansk, 80-219, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-952, Poland
  • Malopolskie Centrum Medyczne Sc
    Krakow, 30-510, Poland
  • Wojewodzki Szpital Specjalistyczny W Legnicy
    Legnica, 59-220, Poland
  • Wielospecjalistyczne Centrum Onkologii I Traumatologii Im M Kopernika W Lodzi
    Lodz, 93-510, Poland
  • Examen Sp Z Oo
    Poznan, 60-569, Poland
  • Hospital Universitari Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital de La Santa Creu I Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitario Vall Dhebron
    Barcelona, 08035, Spain
  • Hospital Clinic I Provincial
    Barcelona, 08036, Spain
  • Ico Girona
    Girona, 17007, Spain
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, 28222, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital Virgen de La Salud
    Toledo, 45004, Spain

Showing the first 100 of 115 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kazmierczak M, Lamanna N, O'Brien SM, Tam CS, Qiu L, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Wang MD, Fu L, Li J, Wu K, Cohen A, Shadman M. Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2023 Jan 26;388(4):319-332. doi: 10.1056/NEJMoa2211582. Epub 2022 Dec 13. PubMed 36511784 ↗
  • Hillmen P, Eichhorst B, Brown JR, Lamanna N, O'Brien SM, Tam CS, Qiu L, Kazmierczak M, Zhou K, Simkovic M, Mayer J, Gillespie-Twardy A, Shadman M, Ferrajoli A, Ganly PS, Weinkove R, Grosicki S, Mital A, Robak T, Osterborg A, Yimer HA, Salmi T, Ji M, Yecies J, Idoine A, Wu K, Huang J, Jurczak W. Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III Trial. J Clin Oncol. 2023 Feb 10;41(5):1035-1045. doi: 10.1200/JCO.22.00510. Epub 2022 Nov 17. PubMed 36395435 ↗
  • Hillmen P, Brown JR, Eichhorst BF, Lamanna N, O'Brien SM, Qiu L, Salmi T, Hilger J, Wu K, Cohen A, Huang J, Tam CS. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol. 2020 Apr;16(10):517-523. doi: 10.2217/fon-2019-0844. Epub 2020 Mar 24. PubMed 32207333 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in Aug 2022, 45 months.

Results were first posted in Jul 2023, 11 months after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 45 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2018
First posted
Nov 7, 2018
StartActual
Nov 1, 2018
Primary completionActual
Aug 8, 2022
CompletionActual
Feb 28, 2024
Results first posted
Jul 27, 2023
Last update
Mar 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03734016
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Nov 7, 2018
Start date
Nov 1, 2018
Primary completion
Aug 8, 2022
Completion
Feb 28, 2024
Results posted
Jul 27, 2023
Last update
Mar 30, 2025

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion